0000000000521843

AUTHOR

Michael Heise

showing 31 related works from this author

Melatonin induces transcriptional regulation of Bim by FoxO3a in HepG2 cells

2012

Background: Melatonin induces apoptosis in many different cancer cell lines, including hepatocellular carcinoma cells. However, the responsible pathways have not been clearly elucidated. A member of the forkhead transcription factors' family, FoxO3a, has been implicated in the expression of the proapoptotic protein Bim (a Bcl-2-interacting mediator of cell death). In this study, we used human HepG2 liver cancer cells as an in vitro model to investigate whether melatonin treatment induces Bim through regulation by the transcription factor FoxO3a. Methods: Cytotoxicity of melatonin was compared in HepG2 hepatoblastoma cells and primary human hepatocytes. Proapoptotic Bim expression was analys…

Transcriptional ActivationCancer Researchmedicine.medical_specialtyProgrammed cell deathSmall interfering RNACarcinoma HepatocellularTranscription GeneticApoptosisFoxO3amelatoninBiologyGenetics & GenomicsMelatoninDownregulation and upregulationCell Line TumorProto-Oncogene ProteinsInternal medicinemedicineTranscriptional regulationHumansGene silencingBimPhosphorylationRNA Small InterferingPromoter Regions GeneticTranscription factorBinding SitesBcl-2-Like Protein 11Forkhead Box Protein O3Membrane ProteinsForkhead Transcription FactorsHep G2 Cellshepatocellular carcinomaCell biologyEndocrinologyOncologyHepatocytesRNA Interferencebiological phenomena cell phenomena and immunityApoptosis Regulatory ProteinsChromatin immunoprecipitationProtein Bindingmedicine.drugBritish Journal of Cancer
researchProduct

Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoprolif…

2010

Long term immunosuppression and therapy of acute rejections result in a 20-120-fold increased risk to develop Non Hodgkin lymphoma (NHL). Since immunosuppressive therapy and immunological disorders are major risk factors for the development of NHL in the non-transplant population we aimed to analyze risk factors for PTLD in our cohort of liver transplanted (LT) patients.We analyzed retrospectively 431 patients liver transplanted between 1998 and 2008.PTLD was diagnosed in eleven of 431 patients (2.6%). PTLD, especially late PTLD, was significantly more frequent in patients who received steroids before LT (Kaplan-Meier: p0.001). Moreover PTLD in immunocompromised patients with preoperative s…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentPopulationAutoimmune hepatitisKaplan-Meier EstimateLiver transplantationGastroenterologyYoung AdultPostoperative ComplicationsRisk Factorshemic and lymphatic diseasesInternal medicinePreoperative CareInternal MedicinemedicineCadaverHumansProspective cohort studyeducationChildAgedProportional Hazards ModelsRetrospective StudiesHepatitiseducation.field_of_studybusiness.industryLymphoma Non-HodgkinRetrospective cohort studyImmunosuppressionMiddle Agedmedicine.diseaseTissue DonorsLymphomaLiver TransplantationHepatitis Autoimmunesurgical procedures operativeImmunologyMultivariate AnalysisFemaleSteroidsbusinessImmunosuppressive AgentsEuropean journal of internal medicine
researchProduct

Acute renal failure and liver dysfunction after subcutaneous injection of 3-sn-phosphatidylcholine (Lipostabil®)-case report.

2011

INTRODUCTION Drug-induced tubulointerstitial nephritis and acute tubular necrosis are common, and are often caused by drugs especially antibiotics or non-steroidal anti-inflammatory drugs. Drug-induced liver dysfunction and renal failure after subcutaneous injection of phosphatidylcholine was not reported so far. 3-sn-Phosphatidylcholine has been described as a cell lysis reaction-inducing drug. Its in vitro data indicated a relevant toxicity potential. In particular human cell types such as fibroblast-like preadipocytes, vascular and skeletal muscle cells, or renal epithelial cells react more sensitive than other human cell types. CASE REPORT We present a 28-year-old woman who received 3.5…

DrugAdultmedicine.medical_specialtymedicine.drug_classNauseamedia_common.quotation_subjectInjections SubcutaneousAntibioticsUrologyRenal functionSubcutaneous injectionmedicineHumansFat embolismAcute tubular necrosismedia_commonNephritisbusiness.industryGastroenterologyAcute Kidney Injurymedicine.diseaseSurgeryToxicityPhosphatidylcholinesFemalemedicine.symptombusinessZeitschrift fur Gastroenterologie
researchProduct

Activation of silent mating type information regulation 2 homolog 1 by human chorionic gonadotropin exerts a therapeutic effect on hepatic injury and…

2017

Incidence and prevalence of inflammatory liver diseases has increased over the last years, but therapeutic options are limited. Pregnancy induces a state of immune tolerance, which can result in spontaneous improvement of clinical symptoms of certain autoimmune diseases including autoimmune hepatitis (AIH). We investigated the immune-suppressive mechanisms of the human pregnancy hormone, chorionic gonadotropin (hCG), in the liver. hCG signaling activates silent mating type information regulation 2 homolog 1 (SIRT1), which deacetylates forkhead box o3 (FOXO3a), leading to repression of proapoptotic gene expression, because the immunosuppressive consequence attributed to the absence of caspas…

0301 basic medicineCD4-Positive T-Lymphocytesmedicine.medical_specialtymedicine.drug_classInflammationAutoimmune hepatitisChorionic GonadotropinSensitivity and SpecificityHuman chorionic gonadotropinImmune tolerance03 medical and health sciencesMiceRandom Allocation0302 clinical medicineImmune systemSirtuin 1Internal medicinemedicineJournal ArticleAnimalsHumansComparative StudyCells CulturedMice Inbred BALB CHepatologybusiness.industryCaspase 3Forkhead Box Protein O3Hepatologymedicine.diseaseDisease Models AnimalHepatitis Autoimmune030104 developmental biologyEndocrinology030220 oncology & carcinogenesisImmunologyHepatocytesFemaleGonadotropinmedicine.symptombusinessHormoneSignal TransductionHepatology
researchProduct

Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma.

2006

Criteria to select patients with hepatocellular carcinoma (HCC) for liver transplantation (LT) are based on tumor size and number of nodules rather than on tumor biology. The present study was undertaken to assess the role of transarterial chemoembolization (TACE) in selecting patients with tumors suitable for LT. Ninety-six consecutive patients with HCC were treated by repeatedly performed TACE, 62 of them exceeding the Milan criteria. Patients meeting the Milan criteria were immediately listed, and patients beyond the listing criteria were listed upon downstaging of the tumor following successful TACE. Fifty patients were finally transplanted. Of these 50 patients, 34 exceeded the Milan c…

Malemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentKaplan-Meier EstimateLiver transplantationMilan criteriaGastroenterologyRecurrenceInternal medicineCarcinomaMedicineHumansChemoembolization TherapeuticSurvival rateRetrospective StudiesTransplantationHepatologybusiness.industryPatient SelectionLiver NeoplasmsRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryLiver TransplantationTransplantationSurvival RateTreatment OutcomeHepatocellular carcinomaRelative riskDisease ProgressionSurgeryFemalebusinessLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
researchProduct

Transarterial Chemoembolization Before Liver Transplantation in 60 Patients With Hepatocellular Carcinoma

2007

Tumor recurrence is a major problem after orthotopic liver transplantation (OLT) in patients with hepatocellular carcinoma (HCC). In 60 patients OLT was performed for HCC after pretreatment by repeated transarterial chemoembolization (TACE). Forty-four recipients exceeded the Milan criteria. Recurrence-free 5-year survival was 65.2% and 5-year freedom from recurrence was 73.2%. During the waiting time, 14 patients experienced minimal change, which did not fulfill the definition of tumor progression according to official oncological criteria. Five-year freedom from recurrence among patients with stable compared with progressive disease was 93.3% versus 28.1%, respectively (P = .0001). A stri…

medicine.medical_specialtyCarcinoma HepatocellularTime Factorsmedicine.medical_treatmentLiver transplantationMilan criteriaGastroenterologyDisease-Free SurvivalRecurrenceInternal medicinePreoperative CaremedicineHumansEmbolizationChemoembolization TherapeuticTransplantationbusiness.industryPatient SelectionLiver Neoplasmsmedicine.diseaseSurvival AnalysisLiver TransplantationSurgeryTransplantationTumor progressionHepatocellular carcinomaSurgerybusinessLiver cancerProgressive diseaseTransplantation Proceedings
researchProduct

Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver

2012

To report the outcome of patients with hepatocellular carcinoma (HCC) in non-cirrhotic liver depending on the mode of primary treatment and to define clinicopathological factors influencing patients' prognosis.A retrospective analysis of an unselected cohort of 105 patients was performed. Overall survival (OS) was estimated by the Kaplan-Meier method and potentially prognostic factors were analyzed in Cox regression models.OS of the whole cohort at 1, 3, and 5 years was 66%, 47%, and 29%, respectively. Tobacco consumption, ECOG0, macroscopic vascular invasion, continuous tumor diameter, and treatment other than resection were predictors of decreased OS in the whole cohort. Resection was per…

AdultLiver CirrhosisMaleOncologymedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentAntineoplastic AgentsRisk FactorsInternal medicinemedicineCarcinomaHepatectomyHumansSurvival analysisAgedNeoplasm StagingRetrospective StudiesAged 80 and overProportional hazards modelbusiness.industryLiver NeoplasmsGastroenterologyRetrospective cohort studyMiddle AgedPrognosismedicine.diseaseSurvival AnalysisBCLC StageTreatment OutcomeLiverHepatocellular carcinomaCohortFemaleHepatectomybusinessFollow-Up StudiesScandinavian Journal of Gastroenterology
researchProduct

Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma--a single-center experience.

2012

Abstract Aims The aim of this study is to evaluate factors associated with the outcome after surgical resection and to compare the efficacy of surgery to transarterial chemoembolisation (TACE) in patients with advanced intrahepatic cholangiocarcinoma (IHC). Materials and methods 273 patients with IHC treated in our department between 1997 and 2012 were included in our study. Patients were divided according to therapy into surgical ( n  = 130), TACE ( n  = 32), and systemic chemotherapy/best supportive care ( n  = 111) groups. Clinicopathological characteristics and survival were reviewed retrospectively. Results The 1-, 3-, and 5-year survival rates in patients after surgical resection were…

AdultLiver CirrhosisMalemedicine.medical_specialtyKaplan-Meier EstimateSingle CenterCholangiocarcinomaHepatic ArteryAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorMedicineHumansChemoembolization TherapeuticLymph nodeIntrahepatic CholangiocarcinomaAgedRetrospective StudiesAged 80 and overUnivariate analysisAnalysis of Variancebusiness.industryBile ductLiver NeoplasmsRetrospective cohort studyGeneral MedicineMiddle AgedSurgerymedicine.anatomical_structureBile Ducts IntrahepaticTreatment OutcomeOncologyBile Duct NeoplasmsChemotherapy AdjuvantResection marginSurgeryFemalePositive Surgical MarginbusinessEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.

2011

Abstract Background Recurrence of hepatocellular carcinoma after orthotopic liver transplantation not amenable to surgical approaches is associated with poor outcome. Aims Retrospective evaluation of the safety and efficacy of sorafenib in patients with post-transplant hepatocellular carcinoma recurrence. Methods Patients with post-transplant hepatocellular carcinoma recurrence were treated with sorafenib. Adverse events were assessed using National Cancer Institute Common Toxicity Criteria of AEs version 3.0, tumour response was evaluated according to Response Evaluation Criteria in Solid Tumours. Results First-line therapy after recurrence was surgery ( n  = 6), radiation therapy ( n  = 1…

OncologySorafenibAdultMaleNiacinamidemedicine.medical_specialtyCarcinoma HepatocellularPyridinesmedicine.medical_treatmentAntineoplastic AgentsLiver transplantationTacrolimusInternal medicinemedicineHumansAdverse effectAgedRetrospective StudiesSirolimusChemotherapyHepatologybusiness.industryPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsGastroenterologyImmunosuppressionMiddle AgedSorafenibmedicine.diseasedigestive system diseasesLiver TransplantationRadiation therapyHepatocellular carcinomaFemaleNeoplasm Recurrence LocalLiver cancerbusinessImmunosuppressive Agentsmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Liver Preservation by Aortic Perfusion Alone Compared With Preservation by Aortic Perfusion and Additional Arterial Ex Situ Back-Table Perfusion With…

2017

Background. Arterial ex situ back-table perfusion (BP) reportedly reduces ischemic-type biliary lesion after liver transplantation. We aimed to verify these findings in a prospective investigation. Methods. Our prospective, randomized, controlled, multicenter study involved livers retrieved from patients in 2 German regions, and compared the outcomes of standard aortic perfusion to those of aortic perfusion combined with arterial ex situ BP. The primary endpoint was the incidence of ischemic-type biliary lesions over a follow-up of 2 years after liver transplantation, whereas secondary endpoints included 2-year graft survival, initial graft damage as reflected by transaminase levels, and fu…

Transplantationmedicine.medical_specialtyHistidine-tryptophan-ketoglutarate solutionbusiness.industrymedicine.medical_treatmentlcsh:SurgeryMedizinlcsh:RD1-811030230 surgeryLiver transplantation019Liver TransplantationLesion03 medical and health sciences0302 clinical medicineMulticenter studyInternal medicinemedicineCardiology030211 gastroenterology & hepatologymedicine.symptombusinessLiver preservationPerfusion
researchProduct

Extended Pancreas Donor Program—The EXPAND Study

2018

BackgroundPancreas transplantation is the only curative treatment option for patients with juvenile diabetes. Organ shortage and restrictive allocation criteria are the main reasons for increasing waitlists, leading to severe morbidity and mortality. We designed a study to increase the donor pool wi

TransplantationPediatricsmedicine.medical_specialtybusiness.industryEconomic shortage030230 surgerymedicine.diseaseTransplantation03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureCurative treatmentMulticenter trialDiabetes mellitusmedicineSevere morbidity030211 gastroenterology & hepatologyPancreasbusinessDonor poolTransplantation
researchProduct

Risk Factors in Patients With Rapid Recurrent Hepatitis C Virus–Related Cirrhosis Within 1 Year After Liver Transplantation

2009

Abstract Background Recurrent cirrhosis (RC) due to pretransplant underlying disease leads to organ failure and subsequent death after orthotopic liver transplantation (OLT). RC occurs in up to 30% of patients with recurrent hepatitis C (HCV) within 5 years after OLT. We sought to identify early risk factors for rapid RC within the first year after OLT in HCV-positive patients. Methods Among 404 liver transplanted patients at the University of Mainz between 1998 and 2008, 90 were HCV-RNA positive. To identify predictive factors for rapid RC, we compared HCV-positive patients with advanced fibrosis stages within 1 year after OLT ( n = 13) with these without RC at 5 years after OLT ( n = 23).…

AdultLiver CirrhosisMalemedicine.medical_specialtyCarcinoma HepatocellularTime FactorsCirrhosismedicine.medical_treatmentHepatitis C virusLiver transplantationmedicine.disease_causeGastroenterologyPredictive Value of TestsRecurrenceRisk FactorsFibrosisInternal medicinemedicineHumansSurvivorsAgedRetrospective StudiesTransplantationbusiness.industryLiver NeoplasmsHepatitis CMiddle AgedViral Loadmedicine.diseaseHepatitis CLiver TransplantationSurgerySurvival RateTransplantationsurgical procedures operativeFemaleSurgeryLiver functionbusinessViral loadFollow-Up StudiesTransplantation Proceedings
researchProduct

Detection of benign hilar bile duct stenoses – A retrospective analysis in 250 patients with suspicion of Klatskin tumour

2016

Introduction The aim of this study was to identify clinical, laboratory and radiological parameters to distinguish benign from malignant stenoses of the proximal bile duct. Methods Between 1997 and 2011, 250 patients were referred to our clinic with hilar bile duct stenoses suspicious for Klatskin tumour. Medical histories, clinical data, pre-interventional laboratory tests, imaging findings, as well as therapeutic approach and patient outcome were compared to final histological results. All data were retrieved from our prospectively maintained database and analysed retrospectively. Results We found benign bile duct lesions in 34 patients (13.6%). Among the entire study population, uni- and…

medicine.medical_specialtySurgical procedureBile ductbusiness.industryGeneral MedicineKlatskin tumourMimicking lesions03 medical and health sciences0302 clinical medicinemedicine.anatomical_structure030220 oncology & carcinogenesisRadiological weaponmedicineRetrospective analysisBenign hilar stenosis030211 gastroenterology & hepatologySurgeryRadiologyDiagnosticbusinessOriginal ResearchAnnals of Medicine and Surgery
researchProduct

Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver tran…

2017

Sebastian Bernuth,1 Daniel Grimm,1 Johanna Vollmar,1 Felix Darstein,1 Jens Mittler,2 Michael Heise,2 Maria Hoppe-Lotichius,2 Peter R Galle,1 Hauke Lang,2 Tim Zimmermann1 1First Department of Internal Medicine, Transplant Hepatology, 2General-, Abdominal- and Transplant- Surgery, University Medical Center, Johannes Gutenberg University, Mainz, Germany Background: Recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) has been a frequent and relevant problem in the past two decades. This analysis evaluated the efficacy and safety of new interferon (IFN)-free direct-acting antiviral (DAA) therapies in a large real-world cohort of HCV patients after LT.Methods: We retrospe…

Liver CirrhosisMaleHepacivirusmedicine.medical_treatmentPharmaceutical ScienceHepacivirusLiver transplantationGastroenterologyCohort Studieschemistry.chemical_compound0302 clinical medicineRecurrenceDrug DiscoveryMedicine030212 general & internal medicineOriginal Researchbiologyliver transplantationvirus diseasesMiddle AgedTreatment OutcomeCohortHCV030211 gastroenterology & hepatologyDrug Therapy CombinationFemalesustained virological responseCohort studymedicine.medical_specialtySVRAntiviral Agentsreinfection03 medical and health sciencesInternal medicineHumansSurvival analysisAgedRetrospective StudiesDAAPharmacologyDrug Design Development and Therapybusiness.industryRibavirinRetrospective cohort studyHepatitis C Chronicbiology.organism_classificationVirologySurvival Analysisdigestive system diseasesDiscontinuationchemistrybusinessDrug design, development and therapy
researchProduct

Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular…

2013

Cholangiocellular carcinoma (CCA) is a primary hepatic malignancy derived from cholangiocytes. The prognosis for CCA patients is very poor and conventional chemotherapy has been proven ineffective in improving long‑term patient survival rates. Organic cation transporters (OCTs) mediate the transport of a broad spectrum of endogenous substrates and the detoxification of xenobiotics. Moreover, OCTs are considered responsible for the responsiveness towards platinum‑based chemotherapies. Currently, there are no data available regarding the role of OCTs in CCA. Therefore, the aim of this study was to investigate the expression of OCT1 and OCT3 in CCA and the corresponding non-neoplastic tumor‑su…

AdultMaleCancer ResearchOrganic Cation Transport ProteinsDown-RegulationKaplan-Meier EstimateBiologySLC22A3CholangiocarcinomaDownregulation and upregulationWestern blotmedicineHumansRNA MessengerAgedAged 80 and overOncogenemedicine.diagnostic_testOrganic Cation Transporter 1CancerMiddle Agedmedicine.diseaseMolecular medicineBile Ducts IntrahepaticBile Duct NeoplasmsOncologyTumor progressionDisease ProgressionCancer researchbiology.proteinImmunohistochemistryFemaleNeoplasm Recurrence LocalInternational Journal of Oncology
researchProduct

The recipient CYP2D6 allele 4-associated poor metabolizer status correlates with an early fibrosis development after liver transplantation

2011

Summary CYP2D6 is part of the cytochrome P450 system, which catalyzes biotransformation of endogenous substrates and xenobiotics. Approximately 10% of the Caucasian population has two null alleles, resulting in a poor metabolizer (PM) status. Mostly, allele four (CYP2D6*4) is responsible for the PM status, which is suspected to be associated with an accelerated fibrosis progression (FP). The aim of the present study was to analyze the role of the CYP2D6*4 genotype for FP after liver transplantation (LT). Genotypes were determined in liver biopsies (donor) and peripheral blood (recipient) by fluorescence resonance energy transfer. Data were correlated with clinical variables and risk factors…

Transplantationmedicine.medical_specialtyCYP2D6business.industrymedicine.medical_treatmentHazard ratioLiver transplantationmedicine.diseaseNull alleleGastroenterologyFibrosisInternal medicineImmunologyGenotypemedicineAllelebusinessAllele frequencyTransplant International
researchProduct

Tacrolimus effects and side effects after liver transplantation: is there a difference between immediate and extended release?

2012

Abstract Background Immunosuppressive therapy after orthotopic liver transplantation (OLT) requires a high degree of patient compliance to guarantee safety and avoid side effects. In 2007, prolonged-release tacrolimus was launched in Europe to improve compliance. In this prospective observational crossover single-center trial, we analyzed effects and side effects of prolonged-release tacrolimus in OLT patients. Methods LT patients at our center were included if they were older than l8 years of age, had had the procedure at least 6 months prior, and were outpatients currently on twice-daily tacrolimus. Patients were observed for 6 months before switching to once-daily tacrolimus. Patient his…

AdultGraft RejectionMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentChemistry Pharmaceuticalchemical and pharmacologic phenomenaLiver transplantationGastroenterologyTacrolimuschemistry.chemical_compoundPharmacotherapyDiabetes mellitusInternal medicineGermanymedicineHumansMedical historyProspective StudiesProspective cohort studyAgedTransplantationCross-Over Studiesbusiness.industryGraft SurvivalMiddle Agedmedicine.diseaseCrossover studyTacrolimusSurgeryLiver Transplantationsurgical procedures operativeTreatment OutcomechemistryDelayed-Action PreparationsSurgeryDrug Therapy CombinationFemaleGlycated hemoglobinbusinessImmunosuppressive AgentsTransplantation proceedings
researchProduct

285 DOWNREGULATION OF ORGANIC CATION TRANSPORTERS OCT1 (SLC22A1) AND OCT3 (SLC22A3) IN HUMAN HEPATOCELLULAR CARCINOMA AND THEIR PROGNOSTIC SIGNIFICAN…

2012

Background Organic cation transporters (OCT) are responsible for the uptake and intracellular inactivation of a broad spectrum of endogenous substrates and detoxification of xenobiotics and chemotherapeutics. The transporters became pharmaceutically interesting, because OCTs are determinants of the cytotoxicity of platin derivates and the transport activity has been shown to correlate with the sensitivity of tumors towards tyrosine kinase inhibitors. No data exist about the relevance of OCTs in hepatocellular carcinoma (HCC).

Organic cation transport proteinsgenetic structuresHepatologybiologyChemistryTransportermedicine.diseaseeye diseasesSLC22A3Downregulation and upregulationHepatocellular carcinomaCancer researchmedicinebiology.proteinsense organsCytotoxicityTyrosine kinaseIntracellularJournal of Hepatology
researchProduct

Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

2016

International audience; BACKGROUND:We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC).METHODS:In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially receiving mammalian target of rapamycin inhibitor-free immunosuppression were randomized 4 to 6 weeks after transplantation into a group on mammalian target of rapamycin inhibitor-free immunosuppression (group A: 264 patients) or a group incorporating sirolimus (group B: 261). The primary endpoint was recurrence-free survival (RFS); intention-to-treat (ITT) analysis was conducted after 8 years. Overal…

MaleTime FactorsIntention to Treat Analysimedicine.medical_treatmentMedizinPROGRESSIONKaplan-Meier EstimateLiver transplantationGastroenterologyImmunosuppressive Agent0302 clinical medicineEVEROLIMUSRENAL-CELL CARCINOMARisk FactorsMedicine and Health SciencesClinical endpointAge FactorSirolimuProspective StudiesIMMUNOSUPPRESSIONTOR Serine-Threonine KinaseTOR Serine-Threonine KinasesHazard ratioLiver NeoplasmsAge FactorsImmunosuppressionMiddle AgedCANCER3. Good healthIntention to Treat AnalysisEuropeRAPAMYCIN INHIBITORSTreatment OutcomeTARGETLocalLiver Neoplasm030220 oncology & carcinogenesisCombinationDisease ProgressionSURVIVAL[SDV.IMM]Life Sciences [q-bio]/Immunology030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleImmunosuppressive Agentsmedicine.drugHumanAdultmedicine.medical_specialtyCanadaCarcinoma HepatocellularTime Factor[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/SurgeryRisk AssessmentDisease-Free Survival03 medical and health sciencesYoung AdultDrug TherapyInternal medicinemedicineHumansAdult; Age Factors; Aged; Australia; Canada; Carcinoma Hepatocellular; Disease Progression; Disease-Free Survival; Drug Therapy Combination; Europe; Female; Humans; Immunosuppressive Agents; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence Local; Prospective Studies; Risk Assessment; Risk Factors; Sirolimus; TOR Serine-Threonine Kinases; Time Factors; Treatment Outcome; Young Adult; Liver Transplantation; TransplantationRECURRENCEMETAANALYSISAgedSirolimusTransplantationEverolimusIntention-to-treat analysisbusiness.industryRisk FactorCarcinomaAustraliaHepatocellular3126 Surgery anesthesiology intensive care radiologySurgeryLiver TransplantationTransplantationProspective StudieNeoplasm RecurrenceSirolimusNeoplasm Recurrence Localbusiness
researchProduct

Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance

2012

Abstract Background Organic cation transporters (OCT) are responsible for the uptake and intracellular inactivation of a broad spectrum of endogenous substrates and detoxification of xenobiotics and chemotherapeutics. The transporters became pharmaceutically interesting, because OCTs are determinants of the cytotoxicity of platin derivates and the transport activity has been shown to correlate with the sensitivity of tumors towards tyrosine kinase inhibitors. No data exist about the relevance of OCTs in hepatocellular carcinoma (HCC). Methods OCT1 (SLC22A1) and OCT3 (SLC22A3) mRNA expression was measured in primary human HCC and corresponding non neoplastic tumor surrounding tissue (TST) by…

AdultMaleCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularOrganic Cation Transport ProteinsHepatocellular carcinomaBlotting WesternDown-RegulationOCT3Real-Time Polymerase Chain ReactionOCT1lcsh:RC254-282SLC22A3Downregulation and upregulationInternal medicineGeneticsmedicineHumansRNA MessengerHCCTyrosineSLC22A3CytotoxicitySLC22A1AgedAged 80 and overOrganic cation transport proteinsbiologybusiness.industryLiver NeoplasmsOrganic Cation Transporter 1TransporterMiddle AgedPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseSurvival AnalysisNeoplasm ProteinsEndocrinologyOncologyHepatocellular carcinomaCancer researchbiology.proteinFemalebusinessTyrosine kinaseResearch ArticleBMC Cancer
researchProduct

Der solid pseudopapilläre Pankreastumor (SPT) – eine seltene Raumforderung der Bauchspeicheldrüse

2008

BACKGROUND: In general, the rare SPT is a tumour of low malignancy predominantly affecting young women. The outcome after radical resection is favourable. In exceptional cases the tumour presents as solid pseudopapillary carcinoma (SPC) with typical malignant features and even metastases. Unresectable liver metastases can be treated with RFA, TACE or chemotherapy. METHODS: We retrospectively reviewed the surgical approach, immunohistochemistry and clinical outcome in five female patients (1998 - 2007). RESULTS: The mean age was 16 years (range: 13 - 47 years). For radical tumour removal a pancreato - duodenectomy (n = 3), a distal pancreatectomy (n = 1) and an enucleation (n = 1) were perfo…

Oncologymedicine.medical_specialtyAngioinvasionChemotherapybusiness.industrymedicine.medical_treatmentEnucleationGastroenterologymedicine.diseaseMalignancyDuodenectomymedicine.anatomical_structureInternal medicinemedicineNeoplasmSolid pseudopapillary tumourRadiologyPancreasbusinessZeitschrift für Gastroenterologie
researchProduct

Organ recipients suffering from undifferentiated neuroendocrine small-cell carcinoma of donor origin: a case report.

2009

Abstract Background Transmission of donor-derived cancer by organ transplantation is rare, but the risk has been increasing due to the aging donor pool. Undifferentiated neuroendocrine small-cell carcinoma is an agressive tumor with the tendency to spread. Herein we have demonstrated different approaches to treat organ recipients with transmitted tumors. Methods and Results Grafts were retrieved from a decreased donor without any history of previous diseases. Autopsy was not performed after donation. The recipient of the liver graft presented with suspected nodules on routine abdominal ultrasound. After computed tomography (CT) scan, biopsy confirmed the diagnosis of a small-cell carcinoma.…

Malemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentAutopsyAntineoplastic AgentsSmall-cell carcinomaNephrectomyOrgan transplantationCarboplatinalpha 1-Antitrypsin DeficiencyBiopsymedicineCarcinomaHumansCarcinoma Small CellNeoplasm MetastasisEtoposideTransplantationChemotherapymedicine.diagnostic_testbusiness.industryLiver NeoplasmsCancerMiddle Agedmedicine.diseaseDNA FingerprintingEmbolization TherapeuticKidney TransplantationTissue DonorsSurgeryLiver TransplantationTransplantationHeart TransplantationSurgerybusinessImmunosuppressive AgentsTransplantation proceedings
researchProduct

Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation-a prospective single-center cohort study

2018

Liver transplantation (LT) is the first-line therapy in patients with transthyretin (TTR) amyloidosis and progressive familial amyloid polyneuropathy (FAP). Explanted organs from these patients can be used for domino liver transplantation (DLT). After DLT, de novo amyloidosis may develop in domino recipients (DR). Data were collected prospectively in a transplant database. Electroneurography by nerve conduction velocity (NCV), quantitative sensory testing, heart rate variability (HRV), sympathetic skin response, orthostatic reaction (tilt table test), transthoracic echocardiography, cardiac MRI and organ biopsy results were evaluated. The cohort included 24 FAP- (11 Val30Met, 13 nonVal30Met…

Transplantationmedicine.medical_specialtybiologymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentAmyloidosis030204 cardiovascular system & hematologyLiver transplantationmedicine.diseaseSingle CenterGastroenterology03 medical and health sciencesTransthyretinTilt table test0302 clinical medicineInternal medicineCohortBiopsybiology.proteinMedicinebusiness030217 neurology & neurosurgeryCohort studyTransplant International
researchProduct

Hepatocellular carcinoma in Child's A cirrhosis: a retrospective analysis of matched pairs following liver transplantation vs. liver resection accord…

2013

This is the first matched pair analysis on the puzzling clinical problem of whether to perform liver transplantation (LT) or liver resection (LR) for Child's A hepatocellular carcinoma (HCC) patients. A total of 201 patients diagnosed with HCC and Child's A liver cirrhosis were treated with LT transarterial chemoembolization (TACE) or LR between 1998 and 2012. To achieve the most accurate study design, two groups of 57 patients were matched retrospectively according to their tumor characteristics detected by the initial computerized tomography (CT) scan. Sixteen of 57 LT candidates were not transplanted due to tumor progress during pre-treatment (TACE). Nevertheless, the retrospective analy…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentMatched-Pair AnalysisMilan criteriaLiver transplantationGastroenterologyResectionRecurrenceInternal medicinemedicineRetrospective analysisHepatectomyHumansIn patientAgedRetrospective StudiesAged 80 and overTransplantationIntention-to-treat analysisbusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseasePrognosisIntention to Treat AnalysisLiver TransplantationSurvival RateHepatocellular carcinomaFemalebusinessFollow-Up StudiesClinical transplantation
researchProduct

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing live…

2010

Abstract Background The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibito…

OncologyCancer ResearchTime Factorsmedicine.medical_treatmentMedizinIntracellular Signaling Peptides and Proteins - antagonists & inhibitors metabolismKaplan-Meier Estimate312 Clinical medicineProtein-Serine-Threonine KinaseLiver transplantationTHERAPYStudy ProtocolImmunosuppressive Agentendothelial growth-factor renal-cell carcinoma tumor progression rapamycin cancer cyclosporine efficacy therapy target model0302 clinical medicineRENAL-CELL CARCINOMARisk FactorsRecurrenceSurgical oncologyMedicine and Health SciencesLiver Neoplasms - drug therapy enzymology mortality surgerySirolimuProspective StudiesTUMOR PROGRESSIONTransplantation Homologoueducation.field_of_studyliver transplantationTOR Serine-Threonine KinasesLiver NeoplasmsIntracellular Signaling Peptides and ProteinsImmunosuppressionhepatocellular carcinomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCANCER3. Good healthEuropeMulticenter StudyTreatment OutcomeTARGETsirolimusOncologyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaRandomized Controlled TrialmTORCarcinoma Hepatocellular - drug therapy enzymology mortality surgery030211 gastroenterology & hepatologyImmunosuppressive AgentsRCTHumanmedicine.drugCanadamedicine.medical_specialtyCarcinoma HepatocellularTime FactoreducationPopulationLiver Transplantation - adverse effects mortalityProtein Serine-Threonine Kinaseslcsh:RC254-282Disease-Free Survival03 medical and health sciencesInternal medicineGeneticsmedicineTransplantation HomologousHumansComparative StudyRapamycinddc:610educationProtein-Serine-Threonine Kinases - antagonists & inhibitors metabolismKaplan-Meiers Estimatebusiness.industryRisk FactorAustraliaImmunosuppressive Agents - therapeutic useSirolimus - therapeutic useEFFICACYHumans; Liver Transplantation; Hepatocellular Carcinoma; Randomized Controlled Trial; RCT; Multicenter Study; Comparative Study; Rapamycin; mTOR; Sirolimusmedicine.diseaseSurgeryMODELTransplantationClinical trialProspective StudieIntracellular Signaling Peptides and ProteinSirolimusENDOTHELIAL GROWTH-FACTORCYCLOSPORINERAPAMYCINbusiness
researchProduct

Results of the TOP Study: Prospectively Randomized Multicenter Trial of an Ex Vivo Tacrolimus Rinse Before Transplantation in EDC Livers

2016

Background. Organ shortage results in the transplantation of extended donor criteria (EDC) livers which is associated with increased ischemia-reperfusion injury (IRI). Experimental studies indicate that an organ rinse with the calcineurin inhibitor tacrolimus before implantation protects against IRI. The tacrolimus organ perfusion study was initiated to examine the effects of ex vivo tacrolimus perfusion on IRI in transplantation of EDC livers. Methods. A prospective randomized multicenter trial comparing ex vivo perfusion of marginal liver grafts (>= 2 EDC according to Eurotransplant manual) with tacrolimus (20 ng/mL) or histidine-tryptophane-ketoglutarate solution (control) was carried ou…

Transplantationmedicine.medical_specialtybiologybusiness.industryUrologyAspartate transaminase030230 surgeryInterim analysisTacrolimusLiver TransplantationSurgeryTransplantationCalcineurin03 medical and health sciencessurgical procedures operative0302 clinical medicineAlanine transaminaseMulticenter trialbiology.proteinmedicineClinical endpoint030211 gastroenterology & hepatologybusinessTransplantation Direct
researchProduct

Surgical therapy of liver cancer: resection and transplantation

2008

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and is estimated to cause approximately half a million deaths per year. Most tumours (80%) develop in cirrhotic livers caused by viral hepatitis C or B and alcoholic liver disease. In the natural course survival depends on the stage of the disease. At an early stage 3-year survival is 65% without treatment, in the intermediate stage between 10% and 50% of patients are reported to be alive after 2 years, and in the final stage median survival only rarely exceeds 6 months. Surgical treatment is capable of doubling survival. The results of local ablative treatment in early carcinoma are very similar to surgical treatment1…

Oncologymedicine.medical_specialtyAlcoholic liver diseasebusiness.industryCancermedicine.diseaseSurgeryTransplantationLiver diseaseHepatocellular carcinomaInternal medicinemedicineStage (cooking)businessLiver cancerViral hepatitis
researchProduct

Radiofrequency ablation as first-line treatment in patients with early colorectal liver metastases amenable to surgery.

2010

Aiming at avoidance of futile surgery, we have tested whether radiofrequency ablation (RFA) may be used as first-line treatment in patients with colorectal metastases (CRLM) occurring within the first year after colorectal surgery.Surgical resection is the standard treatment in patients with CRLM. Major retrospective analyses have identified the interval between colorectal surgery and the occurrence of CRLM to be of prognostic importance. So far, it is unknown whether survival of the respective patients is hampered if RFA is used as first-line treatment.According to a clinical pathway, we have treated patients with CRLM detected within the first year after colorectal surgery preferentially …

AdultMalemedicine.medical_specialtyColorectal cancerRadiofrequency ablationmedicine.medical_treatmentCatheter ablationlaw.inventionlawmedicineHepatectomyHumansIn patientSurvival analysisAgedRetrospective Studiesbusiness.industryLiver NeoplasmsCancerRetrospective cohort studyLength of StayMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryCatheter AblationDisease ProgressionSurgeryFemaleHepatectomyNeoplasm Recurrence LocalbusinessColorectal NeoplasmsAnnals of surgery
researchProduct

Die Leberfunktion vor Lebertransplantation bestimmt das Überleben nach Lebertransplantation beim hepatozellulären Karzinom

2018

GastroenterologyZeitschrift für Gastroenterologie
researchProduct

Ten Years of Simultaneous Pancreas-Kidney Transplantation: A Retrospective Single-Center Analysis of Prospectively Obtained Data

2011

Simultaneous pancreas-kidney transplantation (SPK) is a standardized and life-saving procedure for a patient suffering from both insulin-dependent diabetes mellitus type 1 (IDDM 1) and end-stage diabetic nephropathy. To expand the donor pool and to determine the influence of the preprocurement pancreas suitability scoring system (P-PASS) on pancreas graft survival we retrospectively analyzed our data on SPK.From 1999 to 2010 we performed 55 SPKs, using systemic-enteric drainage as surgical approach. The immunosuppressive therapy was induced with basiliximab; maintenance therapy was based on tacrolimus, mycophenolate mofetil, and steroids. Data were prospectively obtained, analyzed, and corr…

AdultGraft RejectionMalemedicine.medical_specialtyScoring systemCell SurvivalSingle CenterBody Mass IndexDiabetic nephropathyDiabetes mellitusmedicineHumansDiabetic NephropathiesProspective StudiesDonor poolRetrospective StudiesTransplantationbusiness.industryGraft SurvivalSimultaneous pancreas kidney transplantationMiddle Agedmedicine.diseaseKidney TransplantationSurgeryTransplantationDiabetes Mellitus Type 1Treatment Outcomemedicine.anatomical_structureFemaleSurgeryPancreas TransplantationPancreasbusinessImmunosuppressive AgentsTransplantation Proceedings
researchProduct

Extended pancreas donor program – the EXPAND study rationale and study protocol

2013

Background Simultaneous pancreas kidney transplantation (SPK), pancreas transplantation alone (PTA) or pancreas transplantation after kidney (PAK) are the only curative treatment options for patients with type 1 (juvenile) diabetes mellitus with or without impaired renal function. Unfortunately, transplant waiting lists for this indication are increasing because the current organ acceptability criteria are restrictive; morbidity and mortality significantly increase with time on the waitlist. Currently, only pancreas organs from donors younger than 50 years of age and with a body mass index (BMI) less than 30 are allocated for transplantation in the Eurotransplant (ET) area. To address this …

Clinical Trial ProtocolOrgan allocationddc:610Pancreas transplantationRejectionExtended donor criteriaTransplantation Research
researchProduct